Medical Student OMS-IV A.T. Still University KCOM Richmond Heights, Missouri
Introduction: This case highlights the importance of considering linezolid-induced thrombocytopenia as a potential adverse drug reaction in patients receiving linezolid therapy, particularly in those with risk factors such as renal impairment and concomitant heparin therapy. Healthcare providers should be vigilant in monitoring platelet counts and promptly discontinuing linezolid if thrombocytopenia develops. Further research is needed to better understand the mechanism of linezolid-induced thrombocytopenia and identify risk factors to aid in its prevention and management.
Case Study: A 47-year-old female with a past medical history of hypertension, chronic anemia, type 1 diabetes mellitus, and diabetic foot ulcer, was admitted to the hospital with suspected cellulitis. Linezolid was initiated as part of the antibiotic regimen, and unfractionated heparin was administered for thromboprophylaxis of immobility. Further workup ruled out other causes of thrombocytopenia, and linezolid was identified as the probable cause. Linezolid was discontinued, and the patient's platelet count gradually improved over the following week without any other intervention.
Discussion: Linezolid-induced thrombocytopenia is a rare but potentially serious adverse drug reaction. The exact mechanism of thrombocytopenia in this case is not fully understood. In this case, the patient had multiple risk factors, including renal impairment and concomitant unfractionated heparin therapy, which may have contributed to the development of thrombocytopenia. Close monitoring of platelet counts is important during linezolid therapy, especially in patients with risk factors. Prompt recognition and discontinuation of linezolid are crucial to prevent complications associated with severe thrombocytopenia.
